4-aminopyridine has been researched along with Encephalopathy, Traumatic in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We tested clinically relevant dosage of 4-AP as an acute treatment for experimental TBI and found multiple benefits in corpus callosum axons." | 1.72 | Acute axon damage and demyelination are mitigated by 4-aminopyridine (4-AP) therapy after experimental traumatic brain injury. ( Armstrong, RC; Galdzicki, Z; Lischka, FW; Noble, MD; Radomski, KL; Zi, X, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Radomski, KL | 1 |
| Zi, X | 1 |
| Lischka, FW | 1 |
| Noble, MD | 1 |
| Galdzicki, Z | 1 |
| Armstrong, RC | 1 |
1 other study available for 4-aminopyridine and Encephalopathy, Traumatic
| Article | Year |
|---|---|
Acute axon damage and demyelination are mitigated by 4-aminopyridine (4-AP) therapy after experimental traumatic brain injury.
Topics: 4-Aminopyridine; Animals; Axons; Brain Injuries, Traumatic; Female; Male; Mice; Mice, Inbred C57BL; | 2022 |